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Eﬃcacy of Pimobendan in the Prevention of Congestive Heart
Failure or Sudden Death in Doberman Pinschers with Preclinical
Dilated Cardiomyopathy (The PROTECT Study)
N.J. Summerﬁeld, A. Boswood, M.R. O’Grady, S.G. Gordon, J. Dukes-McEwan, M.A. Oyama,
S. Smith, M. Patteson, A.T. French, G.J. Culshaw, L. Braz-Ruivo, A. Estrada, M.L. O’Sullivan,
J. Loureiro, R. Willis, and P. Watson
Background: The beneﬁt of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in
Dobermans is not reported.
Hypothesis: That chronic oral administration of pimobendan to Dobermans with preclinical DCM will delay the onset
of CHF or sudden death and improve survival.
Animals: Seventy-six client-owned Dobermans recruited at 10 centers in the UK and North America.
Methods: The trial was a randomized, blinded, placebo-controlled, parallel group multicenter study. Dogs were
allocated in a 1:1 ratio to receive pimobendan (Vetmedin capsules) or visually identical placebo.The composite primary
endpoint was prospectively deﬁned as either onset of CHF or sudden death. Time to death from all causes was a second-
ary endpoint.
Results: The proportion of dogs reaching the primary endpoint was not signiﬁcantly diﬀerent between groups (P = .1).
The median time to the primary endpoint (onset of CHF or sudden death) was signiﬁcantly longer in the pimobendan
(718 days, IQR 441–1152 days) versus the placebo group (441 days, IQR 151–641 days) (log-rank P = 0.0088). The med-
ian survival time was signiﬁcantly longer in the pimobendan (623 days, IQR 491–1531 days) versus the placebo group
(466 days, IQR 236–710 days) (log-rank P = .034).
Conclusion and Clinical Importance: The administration of pimobendan to Dobermans with preclinical DCM prolongs
the time to the onset of clinical signs and extends survival. Treatment of dogs in the preclinical phase of this common
cardiovascular disorder with pimobendan can lead to improved outcome.
Key words: Cardiology; Cardiovascular; Clinical trials; Evidence based medicine; Survival; Therapy.
Introduction
Dilated cardiomyopathy (DCM) is the most com-mon form of cardiomyopathy in dogs and the
2nd most common form of acquired heart disease in
dogs after myxomatous mitral valve disease (MMVD).
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Abbreviations:
2D two-dimensional
ACE angiotensin converting enzyme
CHF congestive heart failure
CI conﬁdence interval
DCM dilated cardiomyopathy
Doberman Doberman Pinscher
ECG electrocardiogram
Holter 24-hour ambulatory ECG
HR hazard ratio
IQR interquartile range
LVIDD left ventricular internal diameter in diastole
LVIDDN left ventricular internal diameter in diastole normalized
for bodyweight
LVIDS left ventricular internal diameter in systole
LVIDSN left ventricular internal diameter in systole
normalized for bodyweight
MMVD myxomatous mitral valve disease
PROTECT pimobendan randomized occult DCM trial to
evaluate clinical symptoms and time to heart failure
SADRs suspected adverse drug reactions
T4 thyroxine
VPC(s) ventricular premature complex(es)
DD change in diastolic diameter
DS change in systolic diameter
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The prevalence of DCM in Doberman Pinschers
(Dobermans) increases with age1 and the estimated
proportion of purebred Dobermans that develop
DCM in their lifetime is approximately
25–50%.1,2 The clinical stage of DCM is typically
characterized by signs of congestive heart failure
(CHF), with or without cardiac arrhythmias.
DCM in Dobermans is characterized by a
protracted preclinical stage (>2–3 years).3 During the
preclinical stage, progressive left ventricular systolic
dysfunction and dilatation develop with or without
clinically important ventricular and supraventricular
arrhythmias. These arrhythmias often progress in
severity. Sudden death caused by ventricular tachyar-
rhythmia-ﬁbrillation occurs before the onset of CHF
in at least 25–30% of aﬀected Dobermans.4,a,b Once
CHF develops and despite optimal treatment, survival
times in this breed are typically short (2–4 months)5
with a case fatality rate of at least a 90% after 1 year.3
Therapies that prolong the preclinical stage of DCM
could therefore be of great potential beneﬁt. In humans
with preclinical left ventricular systolic dysfunction,
treatment with angiotensin converting enzyme (ACE)
inhibitors and beta adrenergic receptor blockers is
routinely recommended.6 The eﬃcacy of prophylactic
treatment in Dobermans remains unclear with 1 retro-
spective study reporting that benazepril might delay the
progression of preclinical DCM in Dobermans.7 How-
ever, despite the result of this retrospective study and
the recommendations for treatment of human patients,
ACE inhibitors are not widely prescribed in the preclini-
cal stage of DCM, and so aﬀected Dobermans typically
remain untreated until CHF or other clinical signs
develop.
Previous studies have suggested that pimobendan
treatment signiﬁcantly reduces case fatality and morbid-
ity in Dobermans with CHF secondary to DCM.8,9
However, the potential beneﬁt of pimobendan treatment
in delaying the progression of preclinical DCM in Dober-
mans has not previously been evaluated. Pimobendan is a
benzimidazopyridazinone with a potent positive inotro-
pic10 and a vasodilatory11 eﬀect. This combined eﬀect of
preload and afterload reduction, together with positive
inotropic support, could result in a reduction in cardiac
size and ﬁlling pressures in Dobermans with preclinical
DCM. Such beneﬁcial eﬀects could result in prolongation
of the preclinical stage of DCM.
The primary objective of this study was to prospec-
tively evaluate whether the chronic oral administration
of pimobendan in Dobermans with preclinical DCM
could delay the onset of CHF or sudden death.
Further aims of the study were to evaluate the eﬀect
of pimobendan treatment on time to death (all cause),
frequency of ventricular arrhythmia, and heart size.
Materials and Methods
Dogs
Client-owned Dobermans were recruited by cardiologists at 10
centers: 5 in the United Kingdom, 4 in the United States, and 1
in Canada. Recruitment occurred initially in the United Kingdom
and Canada. A protocol amendment including the addition of 4
centers in the United States was made 24 months after recruitment
began. This followed the approval of pimobendan (Vetmedin)c
for the treatment of CHF secondary to DCM and MMVD in that
country. This amendment was implemented to increase enrollment.
In each country, owners were invited to present apparently healthy
Dobermans for screening to determine their eligibility for study
participation.
Enrollment Criteria
Inclusion Criteria. Dogs were eligible for participation in the
study provided that the owner had given informed consent.
Dobermans of either sex were included if they were aged between
4 and 9 years (48–119 months inclusive) and had echocardio-
graphic evidence of preclinical DCM, deﬁned according to
weight-adjusted values of left ventricular internal dimension in
systole (LVIDS) equal to or exceeding those in Table 1. Dogs
screened in Texas were only eligible for inclusion if they were
negative on an immunoﬂuorescent antibody test against Trypano-
soma cruzid at the start of the study.
Exclusion Criteria. Dogs were ineligible for inclusion in the
study if they had any of the following: other cardiac disease
(congenital or acquired); current or previous clinical signs attrib-
utable to DCM; an episode of syncope within the previous
6 months; sustained ( 30 seconds) ventricular tachycardia based
on evaluation of a preinclusion 24-hour ambulatory ECG
(Holter); atrial ﬁbrillation; evidence of other clinically important
systemic disease; received cardiovascular or respiratory medica-
tion(s) including corticosteroids within the previous 6 months; or
undergone a general anesthetic in the previous 28 days. In addi-
tion, female dogs that were pregnant, lactating, or intended for
breeding could not be included.
Because of the potential eﬀect of inadequately controlled
hypothyroidism on systolic function,12 dogs with known hypo-
thyroidism were initially excluded from the study. A protocol
amendment was made after 38 months of the study and subse-
quently hypothyroid dogs were considered eligible for inclusion
provided they met the following criteria: the dog was free from
clinical signs of hypothyroidism at the time of inclusion; a
thyroxine (T4) concentration, measured 4–6 hours after levothy-
roxine administration, was in the reference range for that particu-
lar laboratory; the dose of thyroid supplementation had not been
Table 1. Weight-dependent values for left ventricular
internal diameter in systole above which dogs were
considered to have met the inclusion criterion. LVIDS,
left ventricular internal diameter in systole. (Adapted
for use in this study from unpublished observations on
51 normal Doberman Pinschers. The study conducted
by one of the authors [MOG] assessed the relationship
between left ventricular dimension and body weight
resulting in the equation; predicted LVIDS equals
0.1402 9 BW + 26.7 mm.)
Body Weight (kg) up to: LVIDS  (mm)
25 38.8
30 39.5
35 40.2
40 40.9
45 41.6
50 42.3
1338 Summerﬁeld et al
changed in the 60 days before inclusion; and left ventricular
systolic dilatation (Table 1) persisted despite adequate thyroxine
supplementation.
Study Design
The trial was a randomized, blinded, placebo-controlled,
parallel group, multicenter study. Dogs were allocated in a 1:1
ratio to receive pimobendan (Vetmedin capsules) or visually
identical placebo.
The trial protocol was prepared by independent cardiologists
in conjunction with the sponsor and was approved by an ethical
review committee at all sites where this was required.
The contract between the investigators and the sponsor stipu-
lated that the former group have full access to all results and the
right to independently publish results of the study regardless of
the trial outcome.
Randomization and Allocation
Dogs were randomized in pairs over all study sites and over
the whole study. Randomization was stratiﬁed both by sex (male
or female) and the number of ventricular premature complexes
(VPCs) on a 3-minute electrocardiogram (ECG) trace (<4 VPCs
or  4 VPCs). The randomization sequence was generated as a
single list, based on Study Case Number, which was held by a
single-centralized allocation center. The allocation center was not
at a study center. Following the protocol amendment allowing
hypothyroid dogs to be recruited to the study, a separate, simi-
larly stratiﬁed, randomization list was prepared for these dogs.
Once a dog fulﬁlled the inclusion criteria, that center’s dispenser
telephoned the central allocation center, and was assigned the
next available Study Case Number from the randomization list.
The dispenser was also instructed as to which numbered clinical
supplies should be used for that case, by a numerical code on the
label of each container of trial medication. The role of the dis-
pensers was restricted to the dispensing of appropriate clinical
supplies to dog owners, and the dispenser could identify only
whether a particular case was in “Treatment Group 1” or “Treat-
ment Group 2.” Investigators, owners, and study monitors had
no knowledge of allocations to treatments.
Blinding
The blinding code for the treatment groups was held by one
oﬃce and these individuals had no other role in the study. Prede-
ﬁned procedures were available to permit unblinding of individ-
ual cases in the event of medical emergency. Unblinding could be
achieved by contacting named individuals who held the randomi-
zation list; they could then break the treatment code and inform
the investigator of the treatment the animal was receiving.
Neither the investigators, nor the monitor, nor the sponsor of the
study had access to the randomization list.
Pimobendan and placebo were supplied as visually identical
capsules and supplied in identical white containers. Containers
bore unique numerical codes that enabled dispensers to distinguish
between treatment groups, but could not identify which treatment
group was receiving pimobendan or placebo. Investigators and
owners were unable to distinguish between treatments in any way.
Test Treatments
Both pimobendan (Vetmedin capsules) and the visually identi-
cal placebo were administered at the same dose according to
manufacturer’s recommendations.e All dogs  35.1 kg received
2 9 5 mg pimobendan capsules twice daily (q12h) per os, or the
equivalent number of placebo capsules. All dogs  35.0 kg
received 1 9 5 mg capsule q12h or equivalent placebo. Owners
were instructed to administer the test agent in 2 doses per day,
approximately 12 hours apart, and at least 1 hour before
feeding.e Where animals’ weight changed during the study, doses
were appropriately adjusted during the study.
Concomitant Treatments
Administration of nonsteroidal anti-inﬂammatory drugs and
antibiotics was permitted if deemed necessary by the investigator
during the blinded portion of the study. Hypothyroid dogs were
permitted to receive levothyroxine. If an investigator identiﬁed the
development of ventricular arrhythmias during the study requiring
antiarrhythmic treatment, sotalol treatment was permitted in the
protocol. In the event that the arrhythmia was not responsive to
sotalol, mexiletine was added. The necessity for treatment was
judged by individual investigators. Dogs receiving sotalol with or
without mexiletine remained in the study until the primary endpoint
was reached. After the primary endpoint was reached, surviving
dogs received open label pimobendan (Vetmedin) in addition to any
other treatment deemed appropriate by the investigator.
Schedule of Events
Apparently healthy Dobermans were screened to determine
whether they were eligible for study inclusion. All tests were car-
ried out on nonsedated dogs. Before screening was undertaken, a
complete history was obtained from the owner to ascertain
whether any exclusion criteria were met. Eligible dogs underwent
a physical examination (including body weight, kg), 3-minute
ECG recording, echocardiogram, Holter, routine hematology,
and blood biochemistry including total T4, and dogs in Texas
also had an immunoﬂuorescent antibody test against Trypanosoma
cruzi performed.b In cases suspected of hypothyroidism based
on a low or normal total T4, a free T4 by dialysis, thyroid
stimulating hormone, or both were measured to conﬁrm the
diagnosis. Examinations before inclusion were undertaken
between 0 and 14 days (14 to 0 days) before receiving test
medication. The inclusion date was taken to be the day on
which the dog ﬁrst received test medication (day 0). For dogs
included in the study, a physical examination, echocardiogram,
Holter and routine hematology, and blood biochemistry were
repeated in 1–2 months. Follow-up physical examinations were
subsequently carried out 6 months after enrollment, every
6 months thereafter, and at study end.
The 3-minute ECG trace was performed, with each dog lying
in right lateral recumbency. The total number of VPCs on this
ECG trace was recorded. The presence of arrhythmias other than
VPCs was noted. Dogs that showed any arrhythmia, other than
sinus arrhythmia, during the 3-minute ECG trace were recorded
as “arrhythmia yes.” Dog with no evidence of arrhythmia were
recorded as “arrhythmia no.” Dogs with a total of 4 or more
VPCs during the 3-minute ECG trace were recorded as
“VPC  4,” dogs with fewer VPCs during the 3-minute ECG
were recorded as “VPC < 4.”
Echocardiography was performed in a standard manner.13 The
preinclusion echocardiographic examination (Day 14 to Day 0)
consisted of a two-dimensional (2D), M-mode, and Doppler
examination to rule out other congenital or acquired cardiac
disease (other than DCM). M-mode left ventricular dimensions
in systole (LVIDS) and diastole (LVIDD) were acquired from
the right parasternal short axis view of the heart at the level
of the tips of the papillary muscles. The scheduled follow-up
echocardiographic examination included M-mode-derived short
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axis left ventricular dimensions. All recorded left ventricular
dimensions represented the mean of 5 individual measurements
(consecutive normal cycles when possible).
A Holter was recorded as part of the preinclusion examination
to ensure no dog had sustained ventricular tachycardia (>30 sec).
A 2nd Holter was recorded to re-evaluate rhythm, monitor for
the development of new arrhythmias, and determine if there was
a change in the number of VPCs after initiation of test medica-
tion. In the United Kingdom, all Holter recordings were evalu-
ated by one of the authors (RW).f In Canada and the United
States, all Holter recordings were analyzed by an experienced
technician and the results were validated by another of the
authors (MOG). Parameters reported included number of VPCs
in 24 hours, presence and frequency of complex ventricular
arrhythmias (ie, ventricular pairs, triplets, salvos, or duration of
any episodes of sustained ventricular tachycardia: rate >180 beats
per minute), paroxysmal atrial ﬁbrillation, or both.
Further diagnostic tests could be undertaken at any time if
they were considered indicated by an investigator.
All suspected adverse reactions that occurred during the study
were recorded and reported in accordance with local regulations.
Endpoints
Dogs were considered to have reached the primary endpoint
of the study when CHF or sudden cardiac death occurred. A
diagnosis of CHF was wherever possible supported by evidence
from a thoracic radiograph demonstrating pulmonary edema. All
dogs that died unexpectedly with no other apparent cause for
death were assumed to have experienced sudden cardiac death.
If a dog’s clinical condition precluded obtaining thoracic
radiographs, a clinical diagnosis of CHF was made based on the
opinion of the investigator.
Dogs that died or were euthanized for noncardiac reasons or
dogs that were withdrawn from the study for other reasons
before reaching the primary endpoint were included in the pri-
mary endpoint analysis until they were removed from the study
at which point they were censored. Dogs that died for noncardiac
reasons were included in the all cause mortality analysis, from
which only dogs removed from the study for other reasons or
those still alive at the end of the study were censored.
Dogs that had met the primary endpoint of the study and
remained alive for a suﬃcient time to receive oral medication
were oﬀered open-label pimobendan (Vetmedin) in addition to
standard heart failure treatment and followed until they died or
the end of study. There was no standardized treatment or follow-
up during this open-label phase of the study. Date of death was
recorded as a secondary endpoint. The secondary endpoint was
analyzed as all-cause mortality at the end of the study. This end-
point was not predeﬁned in the protocol.
Outcome Measures
The primary outcome measure of the study was the time to
the primary endpoint measured from the day of beginning the
study medication (day 0). The secondary outcome measure of
all-cause mortality was the time (days) from day 0 to the date of
death attributable to any cause.
The change from before enrollment to re-evaluation (1–2 months)
in LVIDS and LVIDD and the change in frequency of VPCs on the
Holter were also evaluated.
Statistical Methods
Power Analysis. An a priori power analysis was undertaken to
determine the group sizes required for the study. It was estimated
on the basis of previously published data that the median time to
the primary endpoint for the placebo group would be 350 days.a
The period over which recruitment was initially expected to occur
was 1 year and the follow-up period 2 years. In the absence of
any prior data from which to estimate the size of the treatment
eﬀect, the median time to the primary endpoint in the treatment
group was estimated to be 800 days. To have an 80% power
of detecting a diﬀerence between groups with a type I error of
5%, it was estimated that there would need to be 32 dogs in
each group. With an anticipated 10% of patients lost to follow-
up the sample size required was calculated to be 36 dogs in each
group.
Interim Analysis. An interim analysis was not originally
planned as part of the study protocol. However, because of a
prolonged recruitment period and the resulting increased dura-
tion of the study, an interim analysis of the outcome with respect
to the primary endpoint was undertaken 44 months after recruit-
ment to the study began. The interim analysis was performed by
an author (AB) removed from recruitment, data collection, and
evaluation of enrolled dogs, and was undertaken without unblin-
ding. The results of the interim analysis were not revealed to
investigators. Before the interim analysis, actions that would be
taken in the light of particular outcomes were deﬁned. The 2
treatment groups were only compared with respect to the time to
primary endpoint by Kaplan Meier plots, log-rank test, and Cox
proportional hazard analysis. If a diﬀerence between groups had
been found to be signiﬁcant at the P < .05 level, the individual
performing the analysis would have been unblinded. If the diﬀer-
ence, signiﬁcant at the P < .05 level, had been demonstrated in
favor of the placebo group, the trial would have been stopped on
the basis of safety concerns. If the diﬀerence between groups had
been signiﬁcant and in favor of the treatment group at the
P < .001 level, the trial would have been stopped because of
superiority of treatment.14 No prior criteria for futility were
deﬁned.14
Final Analysis. Data were examined by visual plots and appro-
priate statistical tests to determine whether or not they were nor-
mally distributed and had equal variances (Shapiro-Wilk test and
Levene’s test, respectively).
Baseline characteristics of the groups were compared for
homogeneity. Continuous variables that were normally distrib-
uted were compared between the groups by unpaired Student’s
t-tests. Continuous variables that were not normally distributed
were compared between groups by the Kruskal Wallis test. Pro-
portions were compared by the Chi-square or Fisher’s exact test.
Time to event data including time to primary endpoint and
time to the secondary endpoint were compared between treat-
ment groups by Kaplan Meier plots and log-rank tests.
The inﬂuence of treatment and baseline variables on outcome
was estimated by Cox proportional hazards analysis. In these
analyses, LVIDD and LVIDS were normalized for body weight
(LVIDDN and LVIDSN, respectively).15 Baseline variables con-
sidered in the univariable analyses were as follows: age, sex, body
weight, heart rate on physical examination, the presence of any
arrhythmia on the 3-minute ECG, the total number of VPCs on
the 3-minute ECG, the presence of 4 or more VPCs on the
3-minute ECG, the total number of VPCs on the 24-hour ECG,
the presence of a complex arrhythmia on the 24-hour ECG,
LVIDSN, LVIDDN, and treatment.
Variables that showed a signiﬁcant association with the time
to primary endpoint at the 20% level in the univariable analysis
were taken forward into a multivariable model. Because there
were 5 variables that related to the presence or absence of
arrhythmias, only 1 arrhythmia-related variable was entered into
the model. The variable chosen for the model was the presence
of  4 VPCs on the 3-minute ECG, because this was the variable
by which randomization had been stratiﬁed. Two of the variables
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were measures of heart size and therefore only one of these was
entered into the model. Normalized systolic diameter was chosen
as systolic diameter was the main determinant of inclusion to the
study. Analyses were run in a backward stepwise manner and the
variable with the highest P value was eliminated from the model
until all variables in the model had a P value < .05. The sensitiv-
ity of the ﬁnal explanatory model to the arrhythmia-related vari-
able chosen was tested by rerunning the analysis with each other
arrhythmia variable (the presence of any arrhythmia on the 3-
minute ECG, the total number of VPCs on the 3-minute ECG,
the total number of VPCs on the 24-hour ECG, and the presence
of a complex arrhythmia on the 24-hour ECG) substituted into
the ﬁnal model in place of “ 4 VPCs.” The sensitivity of the
ﬁnal model to the heart size variable chosen was tested by substi-
tuting LVIDDN for LVIDSN.
After a model was created in which only signiﬁcant variables
remained, ﬁrst order interactions were examined between all pos-
sible pairs of variables remaining in the model. Interaction terms
were created for each pair of variables and these were then
entered into the model 1 at a time to see if the interaction term
had a signiﬁcant eﬀect. In the event of a signiﬁcant interaction
being discovered, the interaction between the 2 variables was
explored further and the nature of interaction accounted for in
the ﬁnal model.
The inﬂuence of treatment on echocardiographic variables was
examined in the following ways. The LVIDD (mm) and the
LVIDS (mm) obtained at the examination before enrollment
were subtracted from the value of the same variable obtained at
the examination performed approximately 1–2 months after
inclusion. This created the variable delta D (DD, mm) for the
change in diastolic diameter and delta S (DS, mm) for the change
in systolic diameter. Values for DD and DS were compared
between treatment groups by an unpaired Student’s t-test.
The inﬂuence of the magnitude of the change in heart size on
outcome was explored with a second, exploratory, multivariable
Cox proportional hazards model. The change in systolic diame-
ter, LVIDSN, and treatment group were entered into this model.
The inﬂuence of treatment on the number of VPCs on the
Holter was examined in the following way. The total number of
VPCs over 24 hours + 1 was log-transformed to create the nor-
mally distributed variable “Log10 (VPC 24 hours + 1).” The
number 1 was added to avoid the attempted log transformation
of zero. For all dogs for which preinclusion and 2nd visit Holters
were available, paired t-tests were used to compare the number
of VPCs before and after the introduction of treatment in both
treatment groups. The proportions of dogs in each group consid-
ered to have a complex ventricular arrhythmia were compared
before and after the introduction of treatment by a Fisher’s exact
test.
A P value <.049 was considered signiﬁcant for the log-rank
test with respect to the primary endpoint. This adjustment was
because of the conduct of an interim analysis with respect to the
primary endpoint of the study for which a P value of .001 would
have been considered evidence of eﬃcacy. For all other statistical
analyses, P < .05 was considered signiﬁcant.
Statistical analyses were conducted by various computer soft-
ware packages.g
Data Management
Data management was undertaken by an independent data
management company.h All clinical and dispenser records were
collected from all centers. Data were veriﬁed and double entered
into a database by separate individuals. During data entry, the 2
sets of data were compared to verify accuracy of entry of data
and any discrepancies between the 2 databases were explored and
resolved. Blinding was maintained during data entry and audit.
Decisions on censoring and exclusions from the study were made
before unblinding. Unblinding took place only after the database
was locked and an independent statistician had provided the ﬁnal
statistical report.i
In preparation of the manuscript, authors followed the recom-
mendations given in the CONSORT statement for reporting ran-
domized clinical trials.16 This was done to improve the clarity of
the study aim and the transparency of the study conduct, and to
improve the ability of the reader to assess the validity of the
results.
Results
Recruitment to the study began in July 2006 and
ﬁnished in December 2010. Follow-up was continued
for a further 10 months after recruitment had been com-
pleted. An interim analysis was undertaken in February
2010 at which time 60 dogs had been recruited to the
study, of which 27 had reached the primary endpoint.
The criterion for unblinding was not met.
Approximately, 1,000 dogs were screened to deter-
mine whether they met the entry criteria of the study.
Seventy-six dogs were recruited to the study. The out-
come after recruitment for these 76 dogs is summa-
rized in Figure 1. The median time in the study for all
recruited dogs was 427 days. Forty-four dogs reached
the primary endpoint, resulting in an overall event rate
for the study of 58%. The median time in study for
dogs reaching the primary endpoint was 373.5 days.
Ten dogs died or were withdrawn from the study for
other reasons. The median time in study for these dogs
was 445 days. Twenty-two dogs were still alive and
had not reached the primary endpoint at the time of
closure of the study. The median time in study
for these dogs was 529 days. No dogs were lost to
follow-up.
Thirty-nine dogs were randomized to receive pimo-
bendan and 37 were randomized to receive placebo. In
the group administered pimobendan, the median dose
received was 0.453 mg/kg/day (interquartile range
(IQR), 0.310–0.503 mg/kg/day)c. Analyses for homoge-
neity of groups showed no signiﬁcant diﬀerence
between groups for any of the characteristics measured
at baseline (Table 2).
In the placebo group, 25 dogs reached the primary
endpoint, 4 dogs died or were withdrawn for other
reasons, and 8 dogs were alive at the end of the study.
In the pimobendan group, 19 dogs reached the pri-
mary endpoint, 6 dogs died or were withdrawn for
other reasons, and 14 dogs were alive at the end of the
study (Table 3). The proportions of dogs reaching the
primary endpoint were not signiﬁcantly diﬀerent
between groups (P = .1).
The estimated median time to the primary endpoint
was signiﬁcantly longer for dogs receiving pimobendan
(718 days, IQR 441–1152 days) than for dogs receiving
placebo (441 days, IQR 151–641 days) (log-rank
P = .0088) (Figure 2). The median time to reach the
primary endpoint for dogs in the pimobendan group
was 63% (9 months) longer than for those in the pla-
cebo group. When a subanalysis was performed
including only euthyroid dogs, the results were similar.
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The estimated median time to the primary endpoint
was signiﬁcantly longer for dogs receiving pimobendan
(693 days, IQR 441–1,152 days) than for dogs receiv-
ing placebo (441 days, IQR 146–641 days) (log-rank
P = .018). Too few hypothyroid dogs (n = 5) were
included in the study to allow their analysis as a
separate subgroup.
Of the 19 dogs reaching the primary endpoint in the
pimobendan group, 12 (63%) developed CHF and 7
(37%) died suddenly. Of the 25 dogs in the placebo
group that reached the primary endpoint, 17 (68%)
developed CHF and 8 (32%) died suddenly. The pro-
portion of dogs reaching the diﬀerent components of
the primary endpoint in the diﬀerent groups was not
signiﬁcantly diﬀerent (P = .76). Comparing only those
dogs that reached each subendpoint, the median time
to each subendpoint was not signiﬁcantly diﬀerent
between groups (Table 4).
Kaplan Meier plot illustrating the estimated propor-
tion of dogs in each group remaining alive (all-cause
Fig 1. A ﬂow chart indicating the outcome for the 76 dogs enrolled in the study.
Table 2. Selected baseline characteristics in the 2 treatment groups expressed as frequencies and (proportions%)
or medians and [interquartile range]
Variable
Treatment Group
P Value
Pimobendan
(n = 39)
Placebo
(n = 37)
Dog characteristics Age (years) 7.08 [5.9–8.4] 7.17 [6.0–8.0] P = .96
Sex: Male/Female 18/21 (46%/54%) 17/20 (46%/54%) P = .50
Body weight (kg) 36.0 [33.0–40.0] 34.5 [32.6–42.1] P = .88
Physical examination Heart rate (beats/minute) 110 [100–130] 109 [91–120] P = .15
Thyroid status Euthyroid/hypothyroid 37/2 (95%/5%) 34/3 (92%/8%) P = .61
ECG (3 minutes) Arrhythmia on 3-minute
ECG: (yes/no)
11/28 (28%/72%) 11/26 (30%/70%) P = 1.00
Total No. VPCs/3 minutes 0 [0–2] 0 [0–1.5] P = .71
 4 VPCs/3 minutes (yes/no) 8/31 (21%/79%) 5/32 (14%/86%) P = .54
24-hour Holter monitor No. VPCs/24 hours 14.5 [3.75–372.3] 56.0 [6.5–265.5] P = .55
Arrhythmia complexity (yes/no) 3/36 (8%/92%) 6/31 (16%/84%) P = .30
Echocardiography Normalized LVIDS 1.40 [1.33–1.56] 1.43 [1.36–1.57] P = .29
Normalized LVIDD 1.77 [1.72–1.94] 1.81 [1.73–1.94] P = .63
VPC, ventricular premature complex; LVIDS, left ventricular internal dimension in systole; LVIDD, left ventricular internal dimen-
sion in diastole.
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mortality) is illustrated in Figure 3. The estimated
median survival time was signiﬁcantly longer for dogs
receiving pimobendan (623 days, IQR 491–1,531 days)
compared with dogs receiving placebo (466 days, IQR
236–710 days) (log-rank P = .034).
Univariable analysis showed that there was an
increase in the hazard of reaching the primary end-
point in dogs with a greater LVIDSN (hazard ratio
(HR) = 1.836 (95% conﬁdence intervals (CI) = 1.457,
2.315) for a 0.1 unit increase in LVIDSN) and a
greater LVIDDN (HR = 1.482 (95% CI = 1.213,
1.810) for a 0.1 unit increase in LVIDDN) (Fig 4).
There was also a signiﬁcant increase in the hazard of
reaching the primary endpoint in dogs with higher
heart rates on physical examination (HR = 1.17 per
10 bpm increase in heart rate; 95% CI = 1.01, 1.35)
and evidence of arrhythmias (the presence of any
Table 3. Reasons for Censoring of 32 Dogs by Treatment.
Treatment Group
Pimobendan Placebo Total
Euthanasia (noncardiac) Subtotal 4 4 8
Neurological signs/spinal disease 2 0 2
Abdominal hemorrhage, suspected splenic mass 0 1 1
Gastric volvulus 0 1 1
Gastrointestinal obstruction 0 1 1
Mammary carcinoma 1 0 1
Osteosarcoma 0 1 1
Possible lymphoma 1 0 1
Noncompliance Subtotal 2 0 2
Owner noncompliance 1 0 1
Removal by investigator, suspected pulmonary neoplasm 1 0 1
Alive at the end of the study Subtotal 14 8 22
Total 20 12 32
Fig 2. Kaplan Meier survival curves plotting the estimated per-
centage of dogs in each group that have not yet met the primary
endpoint, against time. IQR, interquartile range
Table 4. The number of dogs in each treatment reaching the component parts of the primary endpoint and the
median [IQR] time taken to do so. CHF, congestive heart failure. The comparison between groups compares the
time to subendpoint only for those dogs that reached that subendpoint.
Treatment group
P Value for Comparison (Mann Whitney)Pimobendan Placebo
Number reaching primary endpoint 19 25
Subendpoint: Onset of CHF
Median [IQR] time in days to that endpoint.
N = 12
395 [274.3–969]
N = 17
256 [130.5–536.5]
P = .14
Subendpoint: Sudden cardiac death
Median [IQR] time in days to that endpoint.
N = 7
576 [45–623]
N = 8
141 [54.75–320.3]
P = .15
Fig 3. Kaplan Meier survival curves for the all-cause mortality
analysis, plotting the estimated percentage of surviving dogs in
each group, against time. MST, median survival time; IQR,
interquartile range.
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arrhythmia [if an arrhythmia present; HR = 2.88;
95% CI = 1.53, 5.41] on the resting ECG; greater
number of VPCs on the resting ECG [if  4 VPCs;
HR = 2.36; 95% CI = 1.12, 4.97]; and greater num-
bers of VPCs on the Holter recording [HR = 1.146
for each 1000 VPCs on the Holter ECG; 95%
CI = 1.041, 1.261] were all associated with a worse
outcome) (Fig 4).
The explanatory multivariable model created after
the backward stepwise process, but before consider-
ation of interaction terms, contained 4 variables. These
were treatment group, LVIDSN, baseline heart rate,
and whether or not a dog had  4VPCs. The eﬀect of
treatment remained signiﬁcant when all other arrhyth-
mia variables were substituted for  4 VPCs in the
ﬁnal model and when normalized diastolic diameter
was used in the model instead of normalized systolic
diameter.
Six interaction terms were created examining the
interactions between each of the possible pairs of vari-
ables in the model. There was no signiﬁcant interaction
between treatment and any of the other variables. The
only signiﬁcant interaction was between heart rate and
whether or not a dog had  4VPCs. Dogs were there-
fore categorized into 4 groups according to whether or
not they had a heart rate above or below the median
(110 bpm) at baseline, and whether or not they had
 4 VPCs. Group 1 consisted of 32 dogs with a heart
rate <110 bpm and <4 VPCs; this group was used as
the referent category in the multivariable analysis.
Group 2 consisted of 4 dogs with a heart rate
<110 bpm and  4 VPCs. Group 3 consisted of 31
dogs with a heart rate  110 bpm and <4 VPCs.
Group 4 consisted of 9 dogs with a heart rate
 110 bpm and  4 VPCs.
The signiﬁcant eﬀect of treatment in prolonging the
time to the primary endpoint persisted after adjust-
ment for the inﬂuence of other variables (Table 5).
The hazard ratio from the multivariable analysis for
the eﬀect of treatment implies that dogs in the placebo
group were 3.3 times more likely than those in the
pimobendan group to reach the primary endpoint ﬁrst.
The hazard of reaching the primary endpoint approxi-
mately doubled for every 0.1 unit increase in normal-
ized systolic diameter. Dogs with  4 VPCs and an
above median heart rate were approximately 7 times
more likely to reach the primary endpoint ﬁrst.
Paired Holter data were available for 70 dogs: 37 in
the pimobendan group, and 33 in the placebo group.
All repeat Holters were recorded between 20 and
56 days after initiation of treatment. The median time
to the 2nd Holter recording was 30 days (IQR
27–38.5 days) for the pimobendan group and 33 days
for the placebo group (IQR 29–38 days). The time to
2nd recording was not signiﬁcantly diﬀerent for the
groups (P = .33). Reasons for missing data were as
follows: 1 pimobendan dog had sudden cardiac death;
the other missing pimobendan dog had absent data
because of technical diﬃculties at baseline; 1 placebo
dog had sudden cardiac death; 1 placebo dog had
developed CHF; 1 placebo dog did not have a 2nd
Holter ECG until over 1 year after initiating treat-
ment; and 1 placebo dog had absent data because
of technical diﬃculties. In neither group was there a
Fig 4. A forest plot showing the hazard ratio and 95% conﬁdence intervals associated with variables considered in the univariable anal-
yses with time to the primary endpoint (congestive heart failure or sudden death) as the dependent variable. Circles represent the hazard
ratio and the horizontal bars extend from the lower limit to the upper limit of the 95% conﬁdence interval of the estimate of the hazard
ratio. CHF, congestive heart failure; SCD, sudden cardiac death; LVIDDN, normalized left ventricular internal diameter in diastole;
LVIDSN, normalized left ventricular internal diameter in systole; VPCs, ventricular premature complexes; /10 indicates that the hazard
ratio is for a 10-unit change in the variable of interest; /1000 indicates that the hazard ratio is for a 1000-unit change in the variable of
interest; 910 indicates that the hazard ratio is for a 0.1-unit change in the variable of interest.
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signiﬁcant change in VPCs after treatment [comparison
of log10 (total VPC + 1) pimobendan group P = .93,
placebo group P = .33] (Fig 5A and 5B). Three of the
pimobendan dogs were considered to have complex
ventricular arrhythmias before treatment and 5 to have
complex ventricular arrhythmias afterward (the origi-
nal 3 dogs and 2 additional dogs). Six of the placebo
dogs were considered to have complex ventricular ar-
rhythmias before treatment and 6 to have complex
ventricular arrhythmias afterward. (The 6 dogs with
complex arrhythmias at the 2nd examination consisted
of 4 of the original 6 dogs and 2 dogs not considered
to have complex arrhythmias on the 1st examination.
Of the 2 dogs considered to have complex arrhythmias
at the original examination, but not at the 2nd exami-
nation, 1 dog had died and the other was considered
not to have a complex arrhythmia on the 2nd Holter
examination.) None of the dogs received any antiar-
rhythmic treatment between Holter examinations.
Paired echocardiographic data were available for 73
dogs: 38 in the pimobendan group, and 35 in the
placebo group. Reasons for failure to obtain a 2nd
echocardiographic examination were, in all cases, that
the dogs had already reached the primary endpoint.
All repeat echocardiographic examinations were con-
ducted between 20 and 56 days after the initiation of
treatment. The median time to 2nd examination for
the group receiving pimobendan was 30 days (IQR 27
–37 days) and for the group receiving placebo was
34 days (IQR 30–38.5 days); the diﬀerence in time to
the 2nd recording for the 2 groups was not signiﬁcant
(P = .18). The changes in LVIDS and LVIDD from
the 1st echocardiographic examination to the 2nd
examination are illustrated for both groups in
Figure 6. The median change in LVIDS in the pimob-
endan group was 4 mm [5.0 to 2.48 mm]. The
median change in LVIDS in the placebo group was
0 mm [2.0 to 2.7 mm] (P < .001 for the comparison
between groups). The median change in LVIDD in the
pimobendan group was 3.1 mm [5.0 to 0.07 mm].
The median change in LVIDD in the placebo group
was 0.9 mm [1.6 to 3.7 mm] (P < .001 for the
comparison between groups).
Sotalol treatment was administered to 8 dogs in
total, one of which also received mexiletine. Sotalol
treatment was introduced to 2 dogs in the placebo
group 130 days and 146 days after randomization.
Sotalol treatment was introduced to 6 dogs in the
Table 5. Explanatory multivariable model. HR, hazard ratio; CI, conﬁdence intervals
Variable Sig. P = Hazard ratio (HR)
95.0% CI for HR
Lower Upper
Treatment (pimobendan compared with placebo) <.001 0.299 0.153 0.585
Normalized left ventricular systolic diameter (HR for 0.1 unit increase) <.001 2.024 1.568 2.614
Overall eﬀect of VPCs and heart rate .005
< 4 VPC and heart rate <110 (reference) 1
 4 VPC and heart rate <110 .60 1.406 0.398 4.961
< 4 VPC and heart rate  110 .23 1.543 0.761 3.129
 4 VPC and heart rate  110 compared to <.001 7.044 2.436 20.370
A B
Fig 5. The number of VPCs on the 24-hour ECG before and approximately 1 month after the initiation of treatment in the group
receiving pimobendan (A) and the group receiving placebo (B). Diﬀerences were not signiﬁcant in either group. VPC, ventricular pre-
mature complex. Four datapoints do not appear on the logarithmic scale when the VPC number was zero. These are 2 dogs in the
pimobendan group pretreatment, 1 pimobendan dog post treatment, and 1 placebo dog pretreatment.
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pimobendan group, a median of 242.5 days (range
53–935 days) after randomization.
Results of the exploratory multivariable analysis
examining the inﬂuence of LVIDSN, change in
LVIDS, and treatment on the time to the primary
endpoint are illustrated in Table 6.
None of the suspected adverse reactions or potential
complications resulted in the withdrawal of a dog from
the study (Table 7).
Discussion
This study demonstrates a survival beneﬁt of the
chronic administration of pimobendan initiated in the
preclinical phase of a naturally occurring cardiac
disease in Dobermans. Pimobendan administered to
Dobermans with preclinical DCM prolonged, by
9 months, the median time to the onset of CHF or
sudden death and prolonged the time to death attrib-
utable to all causes.
Screening dogs and cats for preclinical cardiac dis-
ease has become commonplace; however, despite this
practice, no previous prospective study has been able
to fulﬁll the criterion of demonstrating the eﬀectiveness
of a treatment administered in the early stage of the
disease.17 In this study, a large population of appar-
ently healthy Dobermans was screened to identify dogs
with echocardiographic evidence of DCM.
There is limited literature addressing the merits of
treatment of patients with preclinical left ventricular
systolic dysfunction, in both humans and domestic ani-
mals. The 2009 update to the guidelines for the man-
agement of adults with heart failure recommends the
use of ACE inhibitors and beta receptor blockers to
retard the progression of left ventricular systolic dys-
function.6 In the veterinary literature, even less atten-
tion has been focused on attempting to slow the
progression of cardiac remodeling by initiating treat-
ments during the preclinical stage of heart disease.
Two prospective studies assessed the merit of treating
MMVD before the onset of signs.18,19 Both studies
demonstrated no diﬀerence between the treatment
group (enalapril) and the placebo group with respect
to signiﬁcantly delaying the onset of clinical signs of
heart disease—the primary endpoint in both studies.
More recently, and after commencement of the study
A
B
Fig 6. The change in left ventricular diameter occurring within
the ﬁrst 2 months of the study for dogs in which paired observa-
tions were available (73 dogs, 38 receiving pimobendan, and 35
receiving placebo). The change in systolic diameter is illustrated
in Figure 6A and the change in diastolic diameter in Figure 6B.
LVIDS, left ventricular internal diameter in systole; LVIDD, left
ventricular internal diameter in diastole.
Table 6. Exploratory multivariable model. LVIDSN,
normalized left ventricular internal diameter in systole
at baseline; HR, hazard ratio; CI, conﬁdence intervals;
DS, change in left ventricular diameter.
Variable
Sig.
P =
Hazard
Ratio
95.0% CI for
HR
Lower Upper
Treatment (Pimobendan
compared with placebo)
.13 0.565 0.272 1.172
Baseline LVIDSN (HR for
a 0.1-unit change)
<.001 1.841 1.404 2.416
DS (mm) .005 1.164 1.047 1.293
Table 7. Suspected adverse drug reactions (not lead-
ing to withdrawal in 76 dogs)
Suspected Adverse Drug Reactions
Treatment Group
Pimobendan Placebo
Gastrointestinal disorders (eg, emesis,
diarrhea, inappetence)
6 3
Abnormal behavior (eg, lethargy,
confusion, restlessness)
1 2
Head bobbing (transient) after
administration of mexiletine,
condition resolved
1
Increased respiratory rate and
eﬀort with exercise
1
Cough (unexplained cause) 1
Mast cell tumor, left thorax 1
Pulmonary mass and rectal mass 1
Ventricular arrhythmia on
Holter monitor recording
1
Irregular and rapid heartbeats
reported by owner
1
Syncope 4
Total 9 14
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described in this report, a retrospective study suggested
a signiﬁcant delay in the time to onset of CHF or
sudden death for Dobermans with preclinical DCM
that were treated with the ACE inhibitor benazepril.7
Previous studies demonstrating the harmful eﬀects
of some inotropic agents in human heart failure
patients20,21 resulted in concern among veterinary car-
diologists that there may be similar detrimental eﬀects
associated with the chronic administration of inotropic
agents in dogs. There is no evidence in the veterinary
literature that pimobendan administration poses a risk
to dogs with DCM. This study demonstrated no
increased risk of proarrhythmia or sudden death asso-
ciated with pimobendan use in a cohort of Dobermans
with preclinical DCM. Furthermore, pimobendan had
a favorable eﬀect on all-cause mortality. In addition,
neither treatment group showed any signiﬁcant alter-
ation in the frequency of VPCs assessed over a
24-hour period comparing recordings obtained before
and approximately 1 month after initiation of treat-
ment. Taken together these data provide evidence to
suggest that pimobendan treatment in a cohort of
Dobermans with preclinical DCM was not associated
with any worsened arrhythmia.
Although the primary purpose of any clinical trial is
to establish the eﬀectiveness of an intervention, a sec-
ondary beneﬁt of such studies is the ability to study
the eﬀects of other factors recorded at baseline on the
outcome of interest in a well-characterized population.
The ability of a study to do this is limited by the size
of the population of dogs being studied and the num-
ber of dogs in the study that experience the outcome
of interest. In this study, there were 76 dogs of which
44 reached the primary endpoint. By a commonly
applied guideline,22, this should mean that we are able
to determine the eﬀect of approximately 3 other vari-
ables, in addition to treatment, on the outcome of
interest. The study therefore also allowed us to demon-
strate that a reduction in systolic function (indicated
by an increase in LVIDSN), a higher heart rate on
physical examination, and the presence of at least 4
VPCs on a 3-minute ECG strip independently pre-
dicted the time to the primary endpoint. There was an
interaction between heart rate and number of VPCs
whereby the dogs at highest risk were those with
higher than median heart rate and 4 or more VPCs.
These dogs were approximately 7 times more likely to
reach the primary endpoint ﬁrst compared with those
with lower than median heart rate and fewer than 4
VPCs. Important to the primary objective of the study,
the beneﬁcial eﬀect of pimobendan persisted after
adjusting for the eﬀects of these other variables.
In univariable analyses, this study demonstrated that
numerous indicators of the presence of arrhythmias,
whether at least 4 VPCs on a 3-minute ECG or the
frequency of VPCs per 24 hours (Holter), were associ-
ated with an adverse outcome; either onset of CHF or
sudden death. Others have previously reported the
adverse association of VPCs and outcome in dogs and
humans with DCM.5,23 In addition, this study showed
that if a dog had any arrhythmia, supraventricular, or
ventricular, they had a worse outcome when compared
with dogs with no detectable arrhythmia. Lastly, this
study showed the clinical relevance of a simple 3-min-
ute ECG trace to predict outcome; the presence of 4
or more VPCs on the 3-minute ECG trace increased
the risk of reaching the primary endpoint approxi-
mately 2.5-fold.
In this study, LVIDS and LVIDSN were used as
surrogates to assess left ventricular systolic function
and reductions in systolic function were associated
with an adverse outcome. This ﬁnding is in agreement
with others5 and has been well demonstrated in
humans with systolic dysfunction.24
Dobermans have limited genetic variability25 that
permits the examination of a relatively homogenous
population of dogs with preclinical DCM. Such homo-
geneity of disease expression and progression allows
the use of a relatively small sample size to demonstrate
a signiﬁcant treatment eﬀect by eliminating confound-
ing factors that might be found in a more heteroge-
neous population. However, it poses questions
regarding the generalizability of this study’s ﬁndings to
preclinical DCM in other large breed dogs. Interim
results of an ongoing study have already suggested
encouraging evidence of a beneﬁt of pimobendan treat-
ment in Irish Wolfhounds with occult DCM.j
Although it has previously been suggested that DCM
in Dobermans might be diﬀerent to DCM in other
breeds, one recent large retrospective study indicated
that after adjusting for the degree of systolic dilata-
tion, presence of left-sided congestive heart failure, and
ventricular arrhythmia frequency (among other vari-
ables), Dobermans did not have a signiﬁcantly diﬀer-
ent prognosis compared with other breeds with DCM.5
The progression of DCM in dogs and the similarities
in phenotype, pathology, and pathophysiology associ-
ated with DCM across breeds suggest that there is a
potential for similar beneﬁt associated with the admin-
istration of pimobendan in the preclinical phase of
DCM in other breeds, although further prospective
studies would be required to demonstrate this.
The main criterion used to identify Dobermans with
preclinical DCM was an elevated LVIDS. The values
used were derived from studying a normal population
of Dobermans and although these were unpublished at
the time of writing the protocol, similar criteria have
subsequently been described in another study.7 The
validity of this criterion was conﬁrmed by the subse-
quent progression of the disease in a high proportion
of the included dogs to the prespeciﬁed primary end-
point. LVIDS measurements were obtained from
M-mode echocardiographic views and more recently
published data have suggested that other echocardio-
graphic techniques than M-mode may be superior in
the early identiﬁcation of Dobermans with DCM.26
Other studies have demonstrated that Dobermans
can present with only ventricular premature com-
plexes as an indication of the presence of preclinical
DCM.1 As all dogs in our study demonstrated evi-
dence of systolic dilatation at the time of enrollment,
we cannot extrapolate the results of our study to dogs
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that present with VPCs in the absence of systolic
dilatation.
There were several exclusion criteria for enrollment
in this study. Dogs with atrial ﬁbrillation or malignant
ventricular arrhythmias were excluded. In addition,
dogs with signiﬁcant comorbidities such as renal fail-
ure, hepatic failure, and some endocrine disorders were
excluded. A small number (n = 5) of dogs with stable
hypothyroidism were included. Censoring hypothyroid
dogs from analyses of the reported endpoints did not
signiﬁcantly change the results of the analysis or con-
clusions. These entry criteria permitted the inclusion of
the majority of Dobermans with preclinical DCM as
evidenced by our screening data. Nevertheless, the
restricted selection in the enrollment necessitates that
caution is exercised when extending our conclusions to
dogs that meet any of our exclusion criteria.
A number of study design factors, in addition to
those discussed above, increased the potential of this
study to determine the eﬀect of treatment. The dogs
were randomized to ensure equal representation by sex
and by frequency of VPCs. Although sex was not
subsequently shown to have a signiﬁcant inﬂuence on
outcome, the presence or frequency of VPCs was
signiﬁcant even after adjusting for the inﬂuence of
treatment and degree of systolic dilatation in the multi-
variable analysis. Many human and veterinary clinical
trials suﬀer from low event rates (therefore high cen-
soring rates). The duration of this study (5.3 years and
median time in study of 427 days) increased the event
rate and augmented the power of this study to demon-
strate a treatment eﬀect.
Analysis of the follow-up echocardiographic data
showed that the administration of pimobendan led to
a signiﬁcant reduction in LVIDS that was associated
with a positive outcome or reduction in the hazard for
development of the primary endpoint. The reduction
in LVIDS and LVIDD could represent a combination
of augmentation of systolic function, reduction in
afterload, reverse remodeling, or a combination of all
three of these factors. Whatever the cause of the
reduced LVIDS, the exploratory multivariable analysis
showed that the change in LVIDS was highly predic-
tive of subsequent outcome even when the original
LVIDSN was taken into account. The observation that
the baseline LVIDS and subsequent change in systolic
diameter were more predictive of outcome than the
treatment group in this analysis suggests that this
alteration of ventricular size may be one of the pri-
mary ways in which pimobendan mediates its favor-
able eﬀects in this population.
One of the primary requirements for the administra-
tion of any medication, particularly in the preclinical
setting, is that it is safe. This study collected data on
suspected adverse drug reactions (SADRs). There was
no clinically relevant diﬀerence in the frequency or
severity of SADRs between the 2 treatment groups,
thereby providing additional evidence of the safety of
pimobendan in this cohort of dogs.
This study did not follow the outcome for the dogs
that were screened, but not enrolled in the study.
Although this was not a primary objective of the trial,
such data would have permitted a better analysis of
the impact of screening on the population as a whole.
Conclusions
The administration of pimobendan signiﬁcantly pro-
longed, by 9 months, the median time to the onset of
CHF or sudden death in Dobermans with preclinical
DCM and also resulted in prolongation of the time to
death attributable to all causes. This beneﬁcial eﬀect
persisted after adjusting for other baseline variables.
The administration of pimobendan did not increase
the presence of, or frequency of, VPCs or sudden
death in the treatment cohort.
Greater dilatation of the left ventricle in systole,
heart rate on physical examination, and having at least
4 VPCs on a 3-minute ECG strip were independent
predictors of adverse outcome after adjusting for the
eﬀect of treatment.
Dogs treated with pimobendan demonstrated a sig-
niﬁcant reduction in heart size after 30 days. The
degree to which heart size reduced was predictive of
the time to onset of congestive heart failure or sudden
death with greater reductions in size associated with
better outcome.
We believe that our results represent grounds to be
optimistic that pimobendan could also be eﬀective in
dogs of other breeds with similar manifestations of
preclinical DCM, although further studies would be
required to objectively assess the merits of pimobendan
treatment in other breeds with preclinical DCM, or in
Dobermans meeting some of our exclusion criteria.
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